Medicus Pharma Ltd. Collaborates with Reliant AI Inc. on AI-Powered Data Analytics Platform for Clinical Trials
Medicus Pharma Ltd., a biotech company, has signed a letter of intent with Reliant AI Inc., a decision-intelligence company, to collaborate on an AI-powered data analytics platform for clinical trial execution. The platform aims to enhance trial efficiency and patient selection for an upcoming Teverelix clinical study in 2026.
The collaboration will focus on dynamic site selection and patient stratification analyses using AI technology to support Medicus' clinical pipeline. The platform will leverage various datasets to analyze disease burden, geographic distribution, and patient characteristics, with potential expansion into broader feasibility and stratification modules.
The proposed commercial structure for the collaboration includes a one-year, milestone-based services engagement with an aggregate financial commitment not exceeding $200,000. The platform is expected to support Medicus-sponsored studies in 2026 and potentially expand to larger late-stage clinical studies in 2028.
Medicus is currently conducting a Phase 2 clinical study for SKNJCT-003, a treatment for basal cell carcinoma, with promising interim results. The company aims to release topline results in the first quarter of 2026 and secure an end-of-phase 2 meeting with the FDA in the first half of 2026.
In addition to its clinical development programs, Medicus recently acquired Antev Limited, a UK-based biotech company developing Teverelix, a GnRH antagonist for prostate cancer and acute urinary retention. The acquisition expands Medicus' pipeline and potential market opportunities in the biotech sector.
Medicus also announced a collaboration with the Gorlin Syndrome Alliance to provide compassionate access to SkinJect™ for patients with Gorlin Syndrome. The initiative aims to collect real-world data and integrate patient insights into the development of SkinJect™ for this rare disease population.
Overall, Medicus Pharma Ltd. is actively advancing its clinical development programs and expanding its pipeline through strategic collaborations and acquisitions. The company's focus on precision-guided biotech/life sciences innovations positions it for growth and success in the healthcare industry.